The evidence highlights the growing potential of miRNAs as diagnostic biomarkers, therapeutic targets and therapeutic tools in cancer immunotherapy as well as the major challenges associated with efficient delivery, off-target effects, immunogenicity and patient heterogeneity.
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that have emerged as critical regulators of gene expression and key cellular processes in cancer, including tumor cell proliferation, survival, metastasis, and both innate and adaptive immune responses within the tumor microenvironment. Through their ability to modulate immune cell development, differentiation, polarization, antigen presentation, cytokine signaling and immune checkpoint expression, miRNAs play a vital role in shaping immune responses and represent attractive therapeutic candidates for remodeling the tumor immune microenvironment. This review provides a comprehensive overview of the mechanisms through which miRNAs regulate anti-tumor immunity and contribute to immune evasion with particular emphasis on their role in modulating major immune checkpoint pathways, including PD-1/PD-L1, CTLA-4, LAG-3, TIM-3 and CD28-mediated signaling. We further examine the contribution of miRNAs to therapeutic resistance and discuss their potential integration with immune checkpoint blockade, chemotherapy, PARP inhibitors and targeted therapies to enhance antitumor efficacy and overcome treatment resistance. Recent advances in spatial transcriptomics and computational approaches have expanded our understanding of miRNA-mediated regulatory networks at single-cell and tissue levels and provide new insights into tumor–immune interactions. In addition, we evaluate the current progress in the clinical development of miRNA-based therapeutics, including miRNA mimics and inhibitors and discuss the major challenges associated with efficient delivery, off-target effects, immunogenicity and patient heterogeneity. Collectively, the evidence highlights the growing potential of miRNAs as diagnostic biomarkers, therapeutic targets and therapeutic tools in cancer immunotherapy. Continued advances in RNA therapeutics, delivery technologies and multi-omics approaches are expected to accelerate the clinical translation of miRNA-based strategies for personalized cancer therapy.
Improvements in elucidating the molecular mechanisms through which circRNAs influence the efficacy of breast cancer immunotherapy pave the way for improving the prognosis of breast cancer immunotherapy and open new avenues for future research and clinical translation.
Yu Jiang, Ya-Wen Wang, Kai Zhang· Frontiers in Immunology· 0 citations
Immune checkpoint inhibitors (ICIs) have shown promise in cancer therapy by enhancing antitumor immune responses, but patient responses are variable, with some experiencing limited efficacy and others suffering from severe immune-related adverse events (irAEs). Identifying predictive biomarkers for ICI efficacy and tox...
Xi Wang, Baojun Duan, Jun Bai et al.· Molecular Medicine Reports· 0 citations
Investigation of whether miR-155-5p and miR-3535 represent regulators capable of driving coordinated functional reprogramming of both, tumor cells and macrophages found they modulate tumor-intrinsic immune checkpoint expression and functional macrophage polarization in a coordinated way.
The tumor microenvironment (TME) is a complex ecosystem that dynamically regulates tumor progression and therapeutic responses. Within this environment, innate immune cells play prominent dual roles, acting as both critical mediators of anti-tumor surveillance and facilitators of tumor immune escape. This review compre...
Song-Hang Xing, Jia-Yu Zhang, Shuang Wang et al.· Frontiers in Immunology· 0 citations
This review focuses on targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators, and discusses the mechanistic basis of resistance-associated biomarkers.
Chao Wang, Dong Yang· Frontiers in Cell and Develo...· 0 citations
The biogenesis and biological functions of miRNAs are discussed and their regulatory roles in the pathogenesis of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple sclerosis, psoriasis, systemic lupus erythematosus, and atopic dermatitis are examined.
T. Tunç, Serap Yaman Ozer, Sema Mısır· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.